HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. Class A

VERA

0.00

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ: VERA) with a Buy and lowers the price target from $125 to $90.